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Background: IL-10+ regulatory B (Bregs), CD4+Foxp3+ regulatory T (Tregs), and CD4+CXCR5+Foxp3+ follicular regulatory
T (TFR) cells regulate the progression of infection disease. This study aimed at examining how those cells associated with
the development of chronic hepatitis B (CHB) and chronic hepatitis C (CHC) in a Chinese population.
Methods: The numbers of circulating IL-10+ Bregs, Tregs and TFR cells in 31 CHC, 58 CHB patients and 22 healthy
controls (HC) were examined by flow cytometry. The potential association of those cells with clinical measures
was analyzed.
Results: The numbers of CD5+CD19+CD1dhighIL-10+ Bregs, Tregs and TFR cells and the levels of serum IL-10, IFN-γ and
IL-2 in the CHB, and IL-10 and IFN-γ in the CHC patients were significantly higher than that in the HC (p < 0.05).
Furthermore, the numbers of circulating IL-10+ Bregs and the levels of serum IL-10, but not other cytokines tested
were positively correlated with the levels of serum HBV DNA and ALT in the HBeAg− CHB patients as well as HCV
RNA and ALT in CHC patients. Additionally, the numbers of circulating TFR cells were positively correlated with
the levels of serum HBV DNA and ALT in the CHB patients as well as HCV RNA and ALT in the CHC patients.
Conclusions: Increased numbers of circulating IL-10+ Bregs and TFR cells are associated with poor virus eradication
and liver injury in CHB and CHC patients. Furthermore, the levels of serum IL-10 is associated with the hepatic flares.
Keywords: Chronic hepatitis C (CHC), Chronic hepatitis B (CHB), Breg, Follicular regulatory T (TFR), T follicular helper
(TFH), Forkhead box protein 3 (Foxp3), IL-10, HBsAgIntroduction
Hepatitis B virus (HBV) or hepatitis C virus (HCV) infec-
tion remains a serious health problem in the world, par-
ticularly in China. Currently, HBV or HCV infection
affects about 350 or 170 million people worldwide and 93
or 30 million people in China [1]. Persistent infection with
HBV or HCV can cause chronic hepatitis B (CHB) or
chronic hepatitis C (CHC), respectively, and many patients
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unless otherwise stated.cirrhosis, hepatocellular carcinoma (HCC) and end-stage
liver disease [2,3]. More importantly, the pathogenic
process of CHB and CHC is still not fully understood. Pre-
vious studies have shown that poor T cell immunity is as-
sociated with the pathogenesis of CHB and CHC [4,5].
However, the regulation of T cell immunity against HBV
or HCV during the process of CHB or CHC has not been
fully understood.
It is well known that forkhead box protein 3 (Foxp3)+
Tregs can inhibit immune responses [6-9]. Emerging
studies have shown that Tregs can inhibit virus-specific
T cell immunity in the pathogenesis of CHB or CHC
[6-8,10,11]. In addition, CD19+CD5+CD1dhighIL-10+
Bregs and CD1d+CD5+ B10 cells can also inhibit T cell
immunity [12-16] and regulate autoimmunity, infectiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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levels of serum IL-10 and a higher frequency of circulat-
ing Bregs in CHB patients are associated temporally with
hepatic flares in Europeans [23]. However, little is known
about whether and how the numbers of circulating IL-
10+ Bregs are associated with clinical pathogenic features
in Chinese patients with CHB or CHC.
CXCR5+CD4+ T follicular helper (TFH) cells are import-
ant for the formation of germinal center and humoral re-
sponses [24]. Interestingly, recent studies have shown that
a subset of Foxp3 + Bcl6+ TFH cells (defined as follicular
regulatory T (TFR) cells) share many characteristics with
Tregs and inhibit immune responses [25-27]. Currently,
there is little information about the numbers of TFR cells
in humans and there is no report about the numbers of
circulating TFR cells in patients with CHB or CHC and
what the potential role TFR cells play in the pathogenesis
of CHB or CHC. In addition, the potential relationship
among Tregs, IL-10+ Bregs, and TFR cells has not been
explored in Chinese patients with CHB or CHC.
In the present study, we characterized the numbers of
TFR cells, IL-10+ Bregs and Tregs in 31 patients with CHC,
58 patients with CHB and 22 gender-, age-, and ethnicity-
matched healthy controls (HC). We found that the num-
bers of TFR cells, Tregs, CD5+CD19+CD1dhighIL-10+ Bregs
and the levels of serum IL-10 in patients with CHB or CHC
were significantly greater than those in the HC. Further-
more, the numbers of CD5+CD19+CD1dhighIL-10+ Bregs
and the levels of serum IL-10 were correlated positively
with the levels of serum HBV DNA or HCV RNA in the
HBeAg− CHB and CHC patients, respectively. In addition,
the numbers of Tregs, Bregs and TFR cells in CHB and
CHC patients were also correlated with positively the levels
of serum HBV DNA, HCV RNA and ALT in the CHB or
CHC patients, respectively. These data suggest that these
regulatory cells inhibited antigen-specific immunity, con-
tributing to the pathogenesis of CHB or CHC.
Methods
Study subjects
A total of 31 patients with CHC and 58 patients with
CHB were recruited sequentially at the inpatient service
of the First Hospital of Jilin University (Changchun, China)
from September 2009 to June 2013. The experimental
protocol was established, according to the ethical guide-
lines of the Helsinki Declaration and was approved by the
Human Ethics Committee of Jilin University, China. Writ-
ten informed consent was obtained from individual partici-
pants. Individual subjects with CHB were diagnosed, based
on the evidence of serum positive HBsAg and HBV DNA
(HBV-DNA) for at least 6 months. Subjects were excluded
for the CHB group if she/he had hepatitis C, D or G,
HIV infection, autoimmune hepatitis or metabolic liver
disease, HCC, receiving immunosuppressive therapy, orantiviral therapy within 6 months. Patients with CHC
were diagnosed, according to positive detection of serum
anti-HCV antibodies and HCV-RNA (>100 IU/ml) for at
least 6 months. Individuals were excluded from the CHC
group if she/he had serum positive for HBsAg, hepatitis D
or G virus infection and anti-HIV, decompensated cirrho-
sis, HCC, a history of alcohol abuse, seizure disorders, or
active autoimmune disease. Another 22 gender-, age-, and
ethnicity-matched healthy subjects with normal values of
liver function tests and negative serological results of viral
and autoimmune liver diseases served as the HC. All sub-
jects denied being a drug user or having been exposed to
hepatotoxins, based on their knowledge [28]. The demo-
graphic and clinical characteristics of the patients are sum-
marized in Tables 1 and 2.
Clinical index assay
The clinical data of individual subjects enrolled in the
study were collected from the hospital records. These data
included age, sex, and laboratory tests. Their blood sam-
ples were subjected to routine laboratory tests, including
the levels of serum alanine transaminase (ALT) and spar-
tate aminotransferase (AST) by Beckman-coulter LX-20
Biochemistry Automatic Analyzer (Beckman-coulter,
California, USA). The levels of serum HBV-DNA (the
detection limitation ≥50 IU/ml) and HCV-RNA (the
detection limitation ≥100 IU/ml) were tested by
fluorescence-based quantitative PCR and RT-PCR using
specific kits, according to the manufacturers’ instruc-
tion (Haoyuan Diagnostics, Shanghai, China). The con-
centrations of serum anti-HCV, HBsAg, HBsAb, HBeAg,
HBeAb and HBcAb were detected by a dynamic laser light
scattering turbidimetry on a protein analyer (Abbott
Laboratories, North Chicago, USA).
Flow cytometry analysis
Venous blood samples were collected from individual
subjects and peripheral blood mononuclear cells (PBMCs)
were isolated by density-gradient centrifugation using
Ficoll-Paque Plus (Amersham Biosciences, Little Chalfont,
UK). PBMCs at 5 × 105/tube were stained in duplicate
with APC-anti-CD4 (R&D Systems), FITC-anti-CD25 or
isotype-matched controls (BD BioSciences, San Jose, USA)
for 30 min. Furthermore, PBMCs (5 × 105/tube) were also
stained in duplicate with Alexa Fluor 647-anti-CXCR5,
PE-Cy7-anti-CD4 (BD PharMingen, San Diego, USA)
for 30 min. After being washed with Flow Cytomestry
Staining Buffer Solution (e-Bioscience), the cells were
fixed and permeabilized by Cytofix/Cytoperm solution
(e-Bioscience). Subsequently, PBMCs were stained intra-
cellularly with PE-anti-FoxP3 (e-Bioscience) for the detec-
tion of CD4+Foxp3+ and CD4+CXCR5+Foxp3+ T cells,
respectively. At least 50,000 events were analyzed by
FlowJo software (v7.6.2).
Table 1 The demographic and clinical characteristics of participants
Parameters HC (n = 22) CHB (n = 58) CHC (n = 31)
Age (years) 42 (22–74) 48 (25–76) 54 (34–74)
Gender: Female/male 6/16 17/41 9/22
ALT (U/L) 27 (13–38) 125 (13–2463)* 57 (13–201)*
AST (U/L) 25 (10–36) 106 (21–1932)* 67 (16–173)*
HCV RNA level (Log10 IU/ml) NA NA 6.42 (3.69–8.60)*
HBV DNA level (Log10 IU/ml) NA 7.26 (5.03–9.98)* NA
WBC (×109/L) 5.57 (4.3–9.7) 7.26 (4.60–12.5)* 7.13 (4.8–12.3)*
Lymphocytes (×109/L) 1.70 (1.02–2.7) 2.14 (1.36–3.12) 1.92 (1.45–2.48)
HBsAg (IU/ml) NA 29.63 (2.97–306.68)* NA
HBsAb (mIU/ml) NA 1.12 (0–391.73)* NA
HBeAg (S/CO) NA 2.38 (0.03–540.84)* NA
HBeAb (S/CO) NA 1.36 (0.02–24.57)* NA
HBcAb (S/CO) NA 1.04 (0.03–19.17)* NA
HCVAb (S/CO) NA NA 7.28 (1.09–34.6)*
HBeAg (+/−) NA 36/22 NA
Disease duration (month) NA 100.8 (14.4–324) 12 (7–36)
Data shown are real case number or median (range). Normal values: ALT: <40 IU/L; AST: <40 IU/L, WBC: (4.0-10.0) × 10^9/L, Lin#: (0.8-4.0) × 10^9/L, HBsAg: <0.050 IU/mL,
HBsAb: <10.000 mIU/mL, HBeAg: <1.0000 S/CO, HBeAb: <1.000 S/CO, HBcAb: <1.000 S/CO, HCVAb: <1.000 S/CO. HC: healthy control; CHB: Chronic hepatitis B, CHC:
Chronic hepatitis C; HBsAg: hepatitis B surface antigen; HBsAb: hepatitis B surface antibody; HBeAg: hepatitis B e antigen; HBeAb: hepatitis B e antibody; HBcAb:
hepatitis B core antibody. *P <0. 05 vs. the HC.
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duplicate in 24-well plates (106 cells/well) and stimulated
with 50 ng/mL of phorbol myristate acetate (PMA), 1.0 μg/
mL of ionomycin, and 50 ng/mL lipopolysaccharide (LPS,
Sigma-Aldrich, St Louis, MO, USA) in 10% fetal bovine
serum (FBS) RPMI-1640 medium (complete medium) for
2 h at 37°C in 5% CO2 and then exposed to Brefeldin A
(GolgiPlug; BD Biosciences, San Jose, CA, USA) for an
additional 4 h. The cells were harvested, washed with
ice-cold PBS, and stained with APC-anti-CD19, PerCP-
anti-CD5, and PE-anti-CD1d (eBiosciences). The immu-
nostained cells were fixed with 4% paraformaldehyde
for 30 min at room temperature and permeabilized
with 0.5% saponin in 10% FBS in PBS for 30 min at
room temperature. After being washed, the cells were
stained intracellularly with FITC-anti-IL-10 (eBiosciences)
and analyzed by flow cytometry. At least 50,000 events per
sample were analyzed.Table 2 The demographic and clinical characteristics of
HBeAg- and HBeAg+ CHB patients
Parameters HBeAg− HBeAg+
Age (years) 46 (25–76) 48 (29–68)
Gender: Female/male 9/13 8/28
ALT (U/L) 145.5 (21–2463) 86 (13–1803)
AST (U/L) 90 (26–1932) 121.5 (21–1838)
HBV DNA level (Log10 IU/ml) 6.52 (5.25–8.23) 7.62 (5.03–9.98)*
*P <0. 05: the HBeAg+ CHB vs. the HBeAg- CHB.Quantification of IL-10 by enzyme-linked immunosorbent
assay (ELISA)
The concentrations of serum IL-10 in individual subjects
were measured using an ELISA kit, according to manu-
facturer’s instructions (Sunny ELISA Kit, Mutisciences,
Hangzhou, China). Briefly, individual sera at 1:2 dilutions
were subjected in triplicate to ELISA analysis, and the
concentrations of serum IL-10 in individual samples were
calculated, according to the standard curve established
using recombinant human IL-10 provided. The limitation
of detection for serum IL-10 was 0.59 pg/ml.Cytometric bead array (CBA) analysis of serum cytokines
The concentrations of serum cytokines (IL-17A, IFN-γ,
TNF-α, IL-6, IL-4, and IL-2) were determined by CBA
using the CBA kit, according to the manufacture’s proto-
col (CBATM, BD Biosciences, San Joes, USA). Individual
samples were quantified in duplicate on a FACSCalibur
cytometry (BD Biosciences), and the data were acquired
using the CellQuestPro and analyzed by the CBA soft-
ware (Becton Dickinson) [29].Statistical analysis
Data are expressed as median and range or individual
mean values. The difference between the groups was ana-
lyzed by Fisher exact test or Mann–Whitney U nonpara-
metric test using the SPSS 19.0 software. The relationship
between variables was evaluated using the Spearman rank
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statistically significant.
Results
Increased numbers of CD5 + CD19 + CD1dhighIL-10+ Bregs
and elevated levels of serum IL-10 in CHB or CHC patients
To investigate the potential role of IL-10+ Bregs, TFR cells
and Tregs in CHB or CHC patients, 31 patients with
CHC, 58 patients with CHB and 22 gender-, age-, and
ethnicity-matched healthy subjects were recruited. There
was no significant difference in the distribution of age andFigure 1 Flow cytometry analysis of the numbers of circulating IL-10+
(106 cells/well) and stimulated in duplicate with 50 ng/mL of PMA, 1.0 μg/m
for 2 h at 37°C in 5% CO2 followed exposing to Brefeldin A for another 4 h.
with APC-anti-CD19, PerCP-anti-CD5, and PE-anti-CD1d. The immunostained
washed, the cells were stained intracellularly with FITC-anti-IL-10 and analyz
and then on CD19+ B cells for further analysis of total CD19+ B cells, CD5+CD
isotype-matched antibodies served as controls. The levels of serum IL-10 in ind
charts and expressed as the mean values of individual subjects and the differen
cytometry analysis; (B) quantitative analysis of the numbers of total CD19+ B ce
Bregs and the levels of serum IL-10. The horizontal lines indicate the median vagender between the patients and HC (Tables 1 and 2). As
expected, all patients had disease duration more than
6 months, consistent with their chronic state. In compari-
son with that in the HC, abnormally higher levels of serum
ALT, AST, positive HBV DNA, HCV RNA, anti-HCV,
HBsAg, HBeAg, HBsAb, HBeAb, and HBcAb were de-
tected in CHB or CHC patients, respectively. In
addition, significantly greater numbers of WBC, but
similar numbers of lymphocytes were detected patients
with CHB or CHC in this population. More import-
antly, the levels of serum HBV DNA were significantlyB cells. PBMCs from individual subjects were plated in 24-well plates
L of ionomycin, and 50 ng/mL of LPS in complete RPMI-1640 medium
The cells were then harvested, washed with ice-cold PBS, and stained
cells were fixed and permeabilized with 0.5% saponin. After being
ed by flow cytometry. The cells were first gated on living lymphocytes
19+, CD5+CD19+CD1dhigh B cells, CD5+CD19+CD1dhighIL-10+ Bregs. The
ividual subjects were analyzed by ELISA. Data are representative FACS
ce between groups was analyzed by the Kruskal–Wallis test. (A) Flow
lls, CD5+CD19+, CD5+CD19+CD1dhigh B cells, CD5+CD19+CD1dhighIL-10+
lues for different groups.
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HBeAg− CHB patients.
We first characterized the numbers of CD5+CD19+,
CD5+CD19+CD1dhigh B cells and CD5+CD19+CD1dhighIL-
10+ Bregs in these subjects by flow cytometry analysis.
As shown in Figure 1, there was no significant difference
in the numbers of circulating CD19+ B cells among
these three groups of subjects. However, the numbers
of CD5+CD19+, CD5+CD19+CD1dhigh B cells and
CD5+CD19+CD1dhighIL-10+ Bregs in both the CHB
and CHC patients were significantly greater than those in
the HC (p < 0.05) although there was no significant differ-
ence in the numbers of CD5+CD19+CD1dhighIL-10+ Bregs
between the CHB and CHC patients. Analysis of serum
IL-10 indicated that the levels of serum IL-10 in the CHB
and CHC patients were similar and were significantly
higher than that in the HC (p < 0.0001). Stratification ana-
lysis revealed that the levels of serum IL-10 in 36 HBeAg+
CHB patients were significantly higher than that in 22Figure 2 Flow cytometry analysis of the numbers of circulating Tregs
FITC-anti-CD25 or isotype-matched controls for 30 min. After being washed
cells were stained with PE-anti-Foxp3 and the numbers of circulating Tregs
FACS charts and expressed as the mean values of individual subjects and t
(A) Flow cytometry analysis; (B) The numbers of total CD4+ T cells, CD4+CD
effector T cells and the ratios of CD4+CD25+ Foxp3+ Tregs to CD4+Foxp3
different groups of subjects.HBeAg− CHB patients, consistent with a previous obser-
vation [22]. Hence, increased numbers of IL-10+ Bregs
and elevated levels of serum IL-10 existed in patients with
CHB or CHC.
Given that IL-10+ Bregs can promote the development
of Tregs, we examined the numbers of Tregs in these
subjects by flow cytometry. We found that there was
no significant difference in the numbers of circulating
CD4+ T cells among these groups of subjects and
CD4+CD25−Foxp3+ and CD4+CD25+Foxp3+ Tregs be-
tween the CHB and CHC patients in this population
(Figure 2A and B). However, the numbers of circulat-
ing CD4+CD25−Foxp3+ and CD4+CD25+Foxp3+ Tregs
in the CHB and CHC patients were significantly greater
than those in the HC (p < 0.05 for both). In contrast, the
numbers of CD4+Foxp3− effector T cells in CHB and
CHC patients were significantly less than that in the
HC (p < 0.05 for both). As a result, the ratios of Tregs to
CD4+Foxp3− effector T cells in the CHB and CHC patients. PBMC at 5 × 105/tube were stained in duplicate with APC-anti-CD4,
, the cells were fixed and permeabilized with Cytofix/Cytoperm. The
were characterized by flow cytometry analysis. Data are representative
he difference between groups was analyzed by the Kruskal–Wallis test.
25−Foxp3+, CD4+CD25+ Foxp3+ Tregs, CD4+Foxp3+ Tregs, CD4+Foxp3−
− effector T cells. The horizontal lines indicate the median values for
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for both). Interestingly, the numbers of CD4+CD25+Foxp3+
Tregs were positively correlated with the numbers of
CD5+CD19+CD1dhighIL-10+ Bregs in the CHB (R =
0.7213, p < 0.0001) and CHC (R = 0.7432, p < 0.0001)
patients. These data indicate that increased numbers
of CD5+CD19+CD1dhighIL-10+ Bregs are associated
with increased numbers of Tregs in CHB or CHC patients.
Increased numbers of circulating TFH and TFR cells in CHB
or CHC patients
TFH cells regulate the formation of germinal center and
humoral responses, and are involved in the pathogenesis
of CHB and CHC [30,31]. Recently, it has been found that
the TFR cells share many characteristics of CD4+Foxp3+
Tregs, which can express Foxp3 and down-regulate
antigen-specific immune responses [27]. To understand
the role of TFR cells in the pathogenesis of CHB and
CHC, we characterized the numbers of TFR and TFH
cells in these subjects by flow cytometry. We found that
there was no significant difference in the numbers of
CD4+CXCR5+ T cells, CD4+CXCR5+Foxp3+ TFR and
CD4+CXCR5+Foxp3− TFH cells between the CHB and
CHC patients. In contrast, the numbers of TFR cells in
the CHB and CHC patients were significantly greater
than that in the HC while the numbers of TFH cells
were lower in all patients than that in the HC (p < 0.05
for both) in Figure 3. Further analysis indicated that theFigure 3 Flow cytometry analysis of the numbers of circulating TFR a
stained in duplicate with Alexa Fluor 647-anti-CXCR5, PE-Cy7-anti-CD4, Alex
fixed and permeabilized cells via Cytofix/Cytoperm. The cells were stained
by gating initially on living lymphocytes, and then on CD4+ T cells. The iso
FACS charts and expressed as the mean values of individual subjects and t
(A) Flow cytometry analysis; (B) The numbers of CD4+CXCR5+ T cells, CD4+
horizontal lines indicate the median values for individual groups.ratios of TFR to TFH in HBeAg− CHB patients were
significantly lower than that in the HBeAg+ CHB pa-
tients (p = 0.009) and the ratios of TFR to TFH in the
CHC patients, but not in the CHB patients, were also
significantly lower than that in the HC (p = 0.015,
data not shown). In addition, the numbers of TFR
cells were positively correlated with the numbers of
CD4+CD25+Foxp3+ Tregs and CD5+CD19+CD1dhighIL-10+
Bregs in both CHB (R = 0.4613, p = 0.0003; R = 0.4245, p =
0.0009) and CHC (R = 0.5417, p = 0.0008; R = 0.4435, p =
0.0100) patients, respectively. Hence, increased numbers of
TFR cells existed in the CHB or CHC patients.
In addition, we further examined the levels of systemic
cytokine responses in these subjects by CBA. We found
that the concentrations of IL-2 and IFN-γ were signifi-
cantly elevated in the CHB patients, while only IFN-γ sig-
nificantly increased in the CHC patients, as compared with
that in the HC (Figure 4). Furthermore, the concentrations
of serum TNF-α significantly decreased in both CHB and
CHC patients, related to that in the HC. However, there
was no significant change in the levels of serum IL-4, IL-6,
and IL-17A among these groups of subjects in this popula-
tion, consistent with previous findings [32,33]. Moreover,
the levels of serum those cytokines were not significantly
correlated with the numbers of Bregs, Tregs, TFR cells or
the values of any clinical measures tested in these patients.
These data suggest that increased numbers of TFR cells
may contribute to the pathogenesis of CHB and CHC.nd TFH cells. PBMCs were isolated from individual subjects and were
a Fluor-488-anti-Bcl-6 for 30 min. After being washed, the cells were
with PE-anti-Foxp3 and were characterized by flow cytometry analysis
type-matched antibodies were used as controls. Data are representative
he difference between groups was analyzed by the Kruskal–Wallis test.
CXCR5+Foxp3− (TFH) cells, and CD4+CXCR5+Foxp3+ (TFR) cells. The
Figure 4 Analysis of serum cytokines. The concentrations of serum IL-17A, IFN-γ, TNF-α, IL-6, IL-4 and IL-2 were determined by CBA, and their
potential correlations with clinical measures were analyzed. Data are expressed as individual mean values of the different groups of subjects from
three separate experiments.
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elevated levels of serum IL-10 are positively correlated with
the values of clinical measures in the HBeAg− CHB and
CHC patients
To further understand the significance of increased num-
bers of IL-10+ Breg cells in the pathogenesis of CHB and
CHC, we analyzed the potential relationship between the
numbers of CD5+CD19+CD1dhighIL-10+ Bregs and the
values of clinical parameters in the CHB or CHC patients.
The numbers of circulating CD5+CD19+CD1dhighIL-10+
Bregs were positively correlated with the concentrations of
serum HBV DNA (R = 0.7021, p = 0.0003, Figure 5A),
HBsAg (R = 0.6301, p = 0.0017), and ALT (R = 0.6556,
p = 0.0009) in the HBeAg− CHB patients. Similarly, the
levels of serum IL-10 were correlated positively with
the levels of serum HBV DNA (R = 0.7031, p = 0.0002),
HBsAg (R = 0.6925, p = 0.0004) and ALT (R = 0.6093,
p = 0.0025) in the HBeAg− CHB patients. However,
there was no significant association of the numbers of
CD5+CD19+CD1dhighIL-10+ Bregs with the values of
other measures tested in CHB patients (data not shown).
Analysis of CHC patients indicated that the numbers
of circulating CD5+CD19+CD1dhighIL-10+ Bregs were
correlated positively with the levels of HCV RNA (R =
0.5214, p = 0.0024, Figure 5B), ALT (R = 0.4262, p =
0.0190) and AST (R = 0.4211, p = 0.0121). Similarly, theconcentrations of serum IL-10 were correlated positively
with the levels of serum HCV RNA (R = 0.5639, p = 0.001),
ALT (R = 0.4584, p = 0.0079) and AST (R = 0.5198, p =
0.0027) in the CHC patients. However, there was no signifi-
cant association of the numbers of CD5+CD19+CD1dhighIL-
10+ Bregs or the levels of serum IL-10 with the values of
other measures in CHC patients (data not shown). Appar-
ently, increased numbers of CD5+CD19+CD1dhighIL-10+
Bregs and elevated serum IL-10 are associated with HBV
and HCV replication and liver injury in CHB, especially in
the HBeAg− CHB patients, and CHC patients.
Increased numbers of TFR cells are correlated positively
with the levels of serum HBV DNA and HCV RNA in CHB
and CHC patients
To understand the importance of TFR cells, we analyzed
the potential association of the numbers of TFR cells
with the values of clinical measures in CHB and CHC
patients. We found that the numbers of circulating TFR
cells were correlated positively with the levels of serum
HBsAg (R = 0.4080, p = 0.0015, Figure 6A), HBV DNA
(R = 0.3822, p = 0.0031, Figure 6B) and ALT (R = 0.3450,
p = 0.008, Figure 6C) in the CHB patients. Similarly, the
numbers of circulating TFR cells were correlated posi-
tively with the levels of serum HCV RNA (R = 0.5851,
p = 0.0005, Figure 6D) and ALT (R = 0.4997, p = 0.0042,
Figure 5 The correlation analysis between the numbers of CD5+CD19+CD1dhighIL-10+ Bregs and the values of clinical measures in CHB
and CHC patients. The potential correlations between the numbers of CD5+CD19+CD1dhighIL-10+ Bregs and the values of clinical measures in
CHB and CHC patients were analyzed by Spearman’s correlation test. Data shown are the mean values of individual patients. (A) The correlation
analysis in the HBeAg− CHB patients (n = 22). (B) The correlation analyses in the CHC patients (n = 31).
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significant association of the numbers of circulating
TFR cells with the values of other measures in the pa-
tients of this population (data not shown). Therefore,
increased numbers of TFR cells are associated with the
virus replication and liver injury in CHB and CHC patients
in this population.
Discussion
Chronic HBV or HCV infection not only causes continual
liver damages, but also is associated with the development
of cirrhosis and HCC [3,34,35]. Furthermore, recent studies
have found that CHB is associated with the development of
non-Hodgkin lymphoma (NHL), diffuse large B-cell lymph-
oma (DLBCL), follicular lymphoma (FL) and T-cell lymph-
omas (TCL) [36,37]. During the pathogenic process of CHB
and CHC, many patients develop immunodeficiency and
impaired virus-specific responses. However, the mecha-
nisms underlying virus-specific immune impairment have
not been clarified.Immunoregulatory cells, such as IL-10+ Bregs, Tregs and
TFR cells have been shown to down-regulate immunity
[26,38,39]. Our previous studies and those of others have
shown that imbalance of Tregs and effector T cells is asso-
ciated with the pathogenic process of CHB and poor prog-
nosis of CHB patients. Similarly, increased numbers of
circulating Tregs occur in CHC patients, which is associ-
ated with weak immune responses against HCV [40,41]. In
this study, we examined the numbers of circulating Tregs,
IL-10+ Bregs and TFR cells in CHB and CHC patients as
well as HC. We found that the numbers of circulating IL-
10+ Bregs and TFR cells, like Tregs, in the CHB and CHC
patients significantly greater than those in the HC and they
were correlated positively in CHB and CHC patients. Fur-
thermore, the levels of serum IL-10 in the CHB and CHC
patients were significantly higher than that in the HC. It is
possible that IL-10+ Bregs, Tregs and TFR collaborate and
help each other, contributing to the development of virus-
specific immune impairment and virus poor eradication in
CHB and CHC patients.
Figure 6 The correlation analysis between the numbers of TFR cells and the values of clinical measures in CHB and CHC patients. The
potential correlations between the numbers of circulating TFR cells and the values of clinical measures in CHB and CHC patients were analyzed
by Spearman’s correlation test. Data shown are the mean values of individual patients. (A-C) The numbers of circulating TFR cells are positively
correlated with the levels of serum HBV RNA, HBsAg and ALT in the CHB patients (n = 58). (D-E) The numbers of circulating TFR cells are positively
correlated with the levels of serum HCV RNA and ALT in the CHC patients (n = 31).
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sponses [18,42]. IL-10+ Bregs have been shown to inhibit
antigen-presenting activity and immune response [43]. In
this study, we found significantly increased numbers of
circulating IL-10+ Bregs and elevated levels of serum IL-
10 and that the numbers of circulating IL-10+ Bregs were
correlated positively with the levels of serum IL-10 in the
CHB and CHC patients (data not shown). These data sup-
port the notion that IL-10 is an autocrine factor for the
development of IL-10+ Bregs [38]. Furthermore, it has
been shown that IL-10+ B cells are associated with the
hepatic flares of HBeAg− CHB patients [23]. We found
that the numbers of circulating IL-10+ Bregs and the levels
of serum IL-10 were positively correlated with the concen-
trations of serum HBV DNA and ALT in the HBeAg−
CHB patients and also positively with the concentrations
of serum ALT, AST and serum HCV RNA in the CHC pa-
tients. Previous studies have shown that T cell immunity,
particularly for virus-specific CD8+ T cell responses, is
crucial for the control of virus replication and liver-injury
during the pathogenic process of CHB and CHC [44,45].
Given that IL-10 is a potent inhibitor of T cell immunity,
it is possible that IL-10 secreted by Bregs down-regulates
T cell immunity and impairs virus eradication. In addition,
IL-10+ Bregs may promote the development of functional
Tregs, impairing anti-virus T cells immunity. Furthermore,
we also found that the levels of serum IL-2, IFN-γ and
TNF-α were significantly changed in the CHB and CHCpatients. However, the precise mechanisms underlying the
regulatory effect of IL-10+ Bregs and the association of
these regulatory cells with the change in the levels of pro-
inflammatory cytokines remain to be investigated.
TFR cells are important regulators of TFH and humoral
responses [31,46]. We found significantly increased num-
bers of circulating TFR cells in the CHB and CHC patients
and the numbers of circulating TFR cells were correlated
positively with the levels of serum HBV DNA, HBsAg and
ALT in the CHB patients and with the levels of serum
HCV RNA, ALT and AST in the CHC patients. These
findings extended our previous observations of signifi-
cantly higher frequency of TFH cells in CHB and CHC pa-
tients [30,31]. Interestingly, we found that the majority of
CHB and CHC patients produced virus-specific antibodies.
The detectable anti-virus antibodies may stem from in-
creased numbers of TFH cells in the CHB and CHC pa-
tients. More importantly, we found that the ratios of TFR
to TFH in CHC, but not in CHB patients, were correlated
negatively with the levels of serum anti-HCV antibodies in
CHC patients (R = −0.4125, p = 0.0213). These data suggest
that TFR cells may inhibit TFH cells and in turn down-
regulate the ability of virus-specific B cells to produce anti-
bodies. Therefore, there is a significant difference in regu-
lating humoral responses between CHB and CHC patients.
Interestingly, we found that the numbers of circulating
IL-10+ Bregs and the ratios of TFR to TFH in HBeAg+
CHB patients were significantly higher than that in the
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CHB patients has been considered a biomarker for HBV
replication and active status of CHB, IL-10+ Bregs and
TFR cells, together with Tregs, may be more powerful
in down-regulating T cell immunity in the HBeAg+ CHB
patients.
While Tregs functionally inhibit inflammation and pro-
tect the liver from many toxicants induced liver injury
[47,48], we found that the numbers of circulating IL-10+
Bregs and TFR cells were correlated positively with the
levels of serum ALT and AST in the CHB and CHC pa-
tients. The abnormally higher levels of ALT and AST have
been considered liver damages it is unclear how signifi-
cantly increased numbers of circulating IL-10+ Bregs and
TFR cells are associated with the liver injury. IL-10 can in-
hibit inflammation and be a protector of liver injury by in-
ducing Bcl-2 and BclxL expression [49,50], and there is no
direct evidence that IL-10 causes liver injury. Notably,
TGF-β1 can promote liver fibrosis through activation of
the Smad signaling. It is possible that IL-10+ Bregs and
TFR cells may secrete TGF-β1, which activates the Smad
signaling to promote liver fibrosis and to induce other
unknown factors, causing liver injury in those CHB and
CHC patients. We are interested in further investigating
how the increased numbers of circulating IL-10+ Bregs
and TFR cells are associated with elevated levels of liver
injury in CHB and CHC patients.
We recognized that our study had limitations, including
small sample size, the single time-point measurement, and
the lack of longitudinal follow-up, the function analysis of
different subsets of T cells. Therefore, further longitudinal
studies on the function of different subsets of T cells and
B cells in a bigger population are warranted.Conclusion
Our data indicated that significantly increased numbers
of circulating IL-10+ Bregs, TFR, TFH and Tregs in CHB
and CHC patients and the numbers of IL-10+ Bregs and
TFR cells were correlated positively with the levels of
serum HBV DNA, HCV RNA, and ALT in CHB or
CHC patients, respectively. To the best of our know-
ledge, this was the first report about the numbers of
circulating IL-10+ Bregs and TFR in CHB and CHC pa-
tients. Our novel data suggest that increased numbers of
IL-10+ Bregs and TFR, together with Tregs, may be asso-
ciated with impaired eradication of HBV or HCV virus
in CHB or CHC patients. Hence, our findings may provide
new insights into regulation of virus-specific immune
responses and virus replication during the pathogenic
process of CHB and CHC.Competing interests
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